The Medical Cannabis and Wellness UCITS ETF (LON:CBDP) Portfolio Manager Nawan Butt offers his thoughts on the recent $7.2B acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals, and how this deal will affect the medical cannabis sector.
GW Pharmaceuticals makes up 14% of the Medical Cannabis and Wellness UCITS ETF’s portfolio. The fund, that falls under the HANetf umbrella, recently celebrated its one year anniversary, has delivered a return of 39.47% over the past three months and 40.41% over the last 12 months.
Read More: The Medical Cannabis and Wellness ETF PM says GW Pharma deal validates